

# L

\*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat®) SMC No 1324/18	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.	Not available as not recommended in NHS Scotland	<a href="#">168</a>	May 2018
Lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat®) SMC No 1301/18	As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.  SMC restriction: patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.	Available in line with national guidance	<a href="#">167</a>	April 2018
Lacosamide (Vimpat®) (1231/17)	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.	Not available as not recommended for use in NHS Scotland	<a href="#">160</a>	Apr 2017
Lacosamide (Vimpat®) (532/09)	Adjunctive therapy of partial-onset seizures in patients with epilepsy (aged 16 years and older)	GPs may prescribe under the direction of Neurology/ Epilepsy Clinic	<a href="#">101</a> <a href="#">99</a> <a href="#">86</a>	Dec 10/Jan 2011 Aug/Sept 2010 Jan 2009

Lamivudine/zidovudine (Combivir®) (569/09)	HIV in paediatric patients	HOSPITAL ONLY Non-formulary	<a href="#">92</a>	Aug/Sept 2009
Lanadelumab 300mg solution for injection (Takhzyro®) SMC2206	For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. SMC restriction: patients with HAE type I or II, who would otherwise be considered for long-term prophylaxis treatment with C1-esterase inhibitor. SMC restriction: patients with HAE type I or II, who would otherwise be considered for long-term prophylaxis treatment with C1-esterase inhibitor.	Available in line with national guidance <a href="https://www.scottishmedicines.org.uk/medicines-advice/lanadelumab-takhzyro-full-smc2206/">https://www.scottishmedicines.org.uk/medicines-advice/lanadelumab-takhzyro-full-smc2206/</a>	<a href="#">178</a>	Feb 2020
Lanreotide (Somatuline® LA)	Thyrotrophic adenomas	Not recommended	<a href="#">64</a>	2006
Lansoprazole oro-dispersible (Zoton FasTab®)	Hp eradication		<a href="#">60</a> <a href="#">55</a>	2006
Lanthanum carbonate (Fosrenol®) (821/12)	Hyperphosphataemia in chronic renal failure	GPs may prescribe under the direction of the Renal Clinic	<a href="#">123</a> <a href="#">100</a> <a href="#">68</a>	Jan 2013 Oct/Nov 2010 May 2007
Lapatinib (Tyverb®) (925/13)	Adult patients with breast cancer	Not recommended	<a href="#">132</a>	Nov/Dec 2013
Lapatinib (Tyverb®) (768/12)	Advanced or metastatic breast cancer	Not recommended	<a href="#">115</a> <a href="#">97</a> <a href="#">86</a>	Mar/Apr 2012 June/Jul 2010 Jan 2009
Laronidase (Aldurazyme®)	Mucopolysaccharidosis I.	HOSPITAL ONLY	<a href="#">47</a> <a href="#">41</a>	2004
Latanoprost 50 micrograms/mL plus timolol 5mg/mL preservative free eye drops (Fixapost®) SMC2159	Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues. SMC restriction: to use in patients who have proven sensitivity to preservatives.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">175</a>	Aug 2019
Latanoprost (Monopost®)	Glaucoma and ocular hypertension	GPs under the direction of	<a href="#">129</a>	Aug/Sept

(879/13)		ophthalmology  Restricted to patients who require benzalkonium chloride free preparation		2013
Latanoprost (Xalacom®) (432/07)	Reduction of intraocular pressure	Formulary (Ophthalmology specialist list)	<a href="#">76</a>	Jan 2008
Latanoprost (Xalatan®)	Glaucoma	Formulary (Ophthalmology specialist list)	<a href="#">41</a>	2004
Ledipasvir/sofosbuvir 90mg/400mg film-coated tablet (Harvoni®) SMC No 1343/18	Treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years. SMC restriction: genotype 1 and 4 CHC only	Available in line with national guidance	<a href="#">169</a>	July 2018
Ledipasvir/sofosbuvir (Harvoni®) (1030/15)	Treatment of chronic hepatitis C (CHC) in adults.  SMC restriction: genotype 1 and 4 CHC only.	HOSPITAL ONLY - (Hep C clinic) Pending confirmation	<a href="#">146</a>	
Ledipasvir/sofosbuvir (Harvoni®) (1084/15)	For the treatment of genotype 3 chronic hepatitis C (CHC) in adults.  SMC Restriction: patients who are ineligible for or unable to tolerate interferon	Formulary Hospital Use Only (Hepatitis C clinic)	<a href="#">151</a>	Sep/Oct 2015
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2289	As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT). In phase III, randomised studies, lenalidomide maintenance treatment improved progression-free survival in patients with newly diagnosed multiple myeloma who had undergone ASCT compared with placebo or observation. Median overall survival data were supportive of lenalidomide maintenance treatment.	Available in line with national guidance	<a href="#">181</a>	November 2020
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg	In combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular	Available in line with national guidance	<a href="#">181</a>	November 2020

and 25mg hard capsules (Revlimid®) SMC2281	lymphoma (Grade 1 to 3a). In a double-blind phase III study lenalidomide in combination with rituximab, compared with placebo plus rituximab, increased progression-free survival in adults with relapsed or refractory follicular lymphoma (Grade 1 to 3a).			
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2217	As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.	Not available as not recommended for use in NHS Scotland	<a href="#">176</a>	Oct 2019
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC2125	As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.	Not available as not recommended for use in NHS Scotland	<a href="#">172</a>	Dec 2018
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg hard capsules (Revlimid®) SMC 1211/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma	Not available as not recommended for use in NHS Scotland	<a href="#">158</a>	Dec 2016
Lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules (Revlimid®)  SMC No. 1096/15	Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.  SMC Restriction: for use in patients unsuitable for thalidomide-containing regimens	Available in line with national guidance	<a href="#">153</a> <a href="#">157</a>	Jan/Feb 2016 Nov 2016
Lenalidomide (Revlimid®) (942/14)	Transfusion-dependent anaemia	HOSPITAL ONLY (Haematology)	<a href="#">136</a>	Mar/Apr 2014
Lenalidomide (Revlimid®) (441/08)	Multiple myeloma	Formulary NOSCAN Protocol is in development	<a href="#">137</a> <a href="#">96</a> <a href="#">81</a> <a href="#">79</a>	Apr/May 2014 Apr/May 2010 July 2008 May 2008
Lenvatinib 4mg and 10mg hard capsules (Kispplx®)	Treatment of adults with advanced renal cell carcinoma (RCC), in combination with pembrolizumab, as first-line	Available in line with national guidance	<a href="#">190</a>	August 2022

SMC2476	<p>treatment.</p> <p>SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.</p> <p>Lenvatinib offers an additional treatment choice in the therapeutic class of tyrosine kinase inhibitors given in combination with a PD-1/PD-L1 inhibitor for this indication.</p>			
Lenvatinib 4mg and 10mg hard capsules (Kispplx®) SMC2199	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.	Available in line with national guidance	<a href="#">178</a>	Feb 2020
Lenvatinib 4mg hard capsules (Lenvima®) SMC2138	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy	Available in line with local guidance for prescribing.	<a href="#">174</a>	May 2019
Lenvatinib 4mg and 10mg hard capsules (Lenmiva®) SMC 1179/16	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by January 2017.	<a href="#">158</a>	Dec 2016
Lercanidipine 20mg tablet (Zanidip®)	Hypertension	Non-formulary	<a href="#">62</a>	2006
Letermovir 240mg film-coated tablets (Prevymis®) SMC1338/18	<p>For prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).</p> <p>Letermovir, compared with placebo, reduced the incidence of CMV reactivation and disease in CMV-seropositive adults undergoing allogeneic HSCT.</p>	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">174</a>	May 2019
Lercanidipine 20mg tablet (Zanidip®)	Hypertension	Non-formulary	<a href="#">62</a>	2006
Letrozole (Femara®) (251/06)	Invasive early breast cancer	GPs may prescribe under the	<a href="#">108</a>	Aug 2011

		direction of the Oncology Clinic	<a href="#">Protocol 49</a>	2005
Letrozole (Femara®)	Initial adjuvant therapy in early breast cancer		<a href="#">58</a>	2006
Leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe SMC2320	As treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation.  Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">183</a>	March 2021
Leuprorelin acetate 3.75mg (Prostap® SR DCS) and 11.25mg (Prostap® 3 DCS) powder and solvent for prolonged-release suspension for injection in pre-filled syringe SMC2319	As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.  Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">183</a>	March 2021
Levetiracetam (Keppra®) (661/10)	Adjunctive therapy in partial onset seizures in children	GPs may prescribe under the direction of Paediatric Neurology	<a href="#">102</a> <a href="#">77</a> <a href="#">72</a>	Jan/Feb 2011 Mar 2008 Sept 2007
Levetiracetam (Keppra®) (395/07)	Adjunctive therapy in juvenile myoclonic epilepsy (JME)	GPs may prescribe under the direction of Paediatrics or Adult Neurology	<a href="#">77</a> <a href="#">72</a>	Mar 2008 Sept 2007
Levetiracetam (Keppra®) (396/07)	Adjunctive therapy in primary generalised tonic-clonic seizures (PGTC)	GPs may prescribe under the direction of Paediatrics or Adult Neurology	<a href="#">77</a> <a href="#">72</a>	Mar 2008 Sept 2007

Levetiracetam (Keppra®) (397/07)	Monotherapy in partial onset seizures	GPs may prescribe under the direction of Paediatrics or Adult Neurology	<a href="#">77</a> <a href="#">72</a>	Mar 2007 Sept 2007
Levetiracetam infusion (Keppra®)	Adjunctive therapy in partial onset seizures in patients over 4 years of age	HOSPITAL ONLY	<a href="#">62</a>	2006
Levetiracetam oral solution (Keppra®)	Adjunctive therapy in partial onset seizures in adults		<a href="#">48</a>	2005
Levetiracetam 750mg film-coated tablets (Keppra®)	Adjunctive therapy in partial onset seizures in adults		<a href="#">48</a>	2005
Levodopa/carbidopa/entacapone (Stalevo®)	Parkinson's disease		<a href="#">36</a> <a href="#">35</a>	2004
Levofloxacin 5mg/ml plus dexamethasone 1mg/ml eye drops solution (Duressa®) SMC2511	For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">191</a>	Nov 2022
Levofloxacin 240mg nebuliser solution (Quinsair®)	The management of chronic pulmonary infections due to psudomonas aeruginosa in adult patients with cystic fibrosis	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">156</a>	Sep 2016
Levomepromazine (Nozinan®)	Palliative care		<a href="#">93</a>	Oct/Nov 2009
Levonorgestrel 19.5mg intrauterine delivery system (Kyleena®) SMC No 1299/18	Contraception for up to 5 years	Available in line with national guidance	<a href="#">167</a>	April 2018
Levonorgestrel (Upostelle®)	Emergency contraception	Formulary - 1st line choice	<a href="#">135</a>	Feb/Mar 2014

(938/14)				
Levonorgestrel (Jaydess®) (1036/15)	Contraception for up to 3 years.	Formulary - 2nd line choice	<a href="#">147</a>	Apr 2015
Levonorgestrel (Levosert®) 20 micrograms/24 hours intrauterine delivery system (1058/15)	Contraception. Heavy menstrual bleeding.	Non Formulary  Lack of clinician demand	<a href="#">149</a>	Jun/Jul 2015
Lidocaine 70mg/tetracaine 70mg medicated plaster (Rapydan®) (483/08)	Surface anaesthesia	Not recommended	<a href="#">80</a>	June 2008
Lidocaine 5% medicated plaster (Versatis®)	Restricted off label use in palliative care or restricted off label use in localised neuropathic pain	GPs may prescribe under the direction of Palliative Care or the Pain Clinic (Chronic Pain Team)	<a href="#">109</a> <a href="#">Protocol</a> <a href="#">99</a>	Sept 2011 Aug/Sept 2010
Lidocaine 5% medicated plaster (Versatis®) (334/06)	Post-herpetic neuralgia	Formulary	<a href="#">109</a> <a href="#">82</a> <a href="#">67</a>	Sept 2011 Aug/Sept 2008 Mar 2007
Linaclootide (Constella®) (869/13)	Moderate to severe irritable bowel syndrome with constipation (IBS-C)	Formulary	<a href="#">129</a> <a href="#">128</a>	Aug/Sept 2013 June/July 2013
Linagliptin plus metformin (Jentadueto®) (1057/15)	For the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.	Non Formulary	<a href="#">149</a>	Jun/Jul 2015



		Lack of clinician demand		
Linagliptin 5mg film-coated tablets (Trajenta®) (850/13)	Type 2 diabetes mellitus to improve glycaemic control in adults	<p>Monotherapy Non-formulary - alternatives preferred Triple therapy with SU + metformin Non-formulary - alternatives preferred Combination with insulin Not recommended In combination with insulin with or without metformin Non Formulary - Lack of clinician support</p>	<p><a href="#">125</a></p> <p><a href="#">148</a></p>	<p>Mar/Apr 2013</p> <p>May 2015</p>
Linagliptin plus metformin (Jentadueto®) (841/13)	Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control	Non-formulary - alternatives preferred	<a href="#">125</a>	Mar/Apr 2013
Linagliptin (Trajenta®) (746/11)	Type 2 diabetes mellitus	<p>Monotherapy: not recommended Dual therapy in combination with metformin: Non-formulary - alternatives preferred Triple therapy: Not recommended</p>	<p><a href="#">116</a></p> <p><a href="#">114</a></p>	<p>Apr/May 2012</p> <p>Feb 2012</p>
Lipegfilgrastim (Lonquex®) (908/13)	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults	Pending OHMMG decision	<a href="#">137</a>	Apr/May 2014
Liposomal formulation of daunorubicin/cytarabine 44mg/100mg powder for concentrate for solution for	The treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia-related changes. In a randomised phase III study, in adults (aged 60 to 75 years) with high risk AML, liposomal	Available in line with national guidance	<a href="#">174</a>	May 2019

infusion (Vyxeos®) SMC2130	daunorubicin/cytarabine improved overall survival when compared with a standard of care regimen.			
Liposomal irinotecan hydrochloride trihydrate (as irinotecan sucrosfate salt), 5mg/mL concentrate for solution for infusion (Onivyde®) SMC No. 1217/17	Treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil (5-FU) and leucovorin (folinic acid), in adult patients who have progressed following gemcitabine based therapy.	Not available as not recommended for use in NHS Scotland	<a href="#">160</a>	Apr 2017
Liraglutide 6mg/ml solution for injection in pre-filled pen (Saxenda®) SM2455	<p>Is accepted for restricted use within NHSScotland.</p> <p>Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:</p> <ul style="list-style-type: none"> <li>• <math>\geq 30 \text{ kg/m}^2</math> (obese), or</li> <li>• <math>\geq 27 \text{ kg/m}^2</math> to <math>&lt; 30 \text{ kg/m}^2</math> (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea</li> </ul>	Not routinely available as local implementation plans are being developed - decision expected by September 2022	<a href="#">189</a>	May 2022
liraglutide 6mg/mL solution for injection in pre-filled pen (Saxenda®) SMC2378	<p>as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:</p> <ul style="list-style-type: none"> <li>• <math>\geq 30 \text{ kg/m}^2</math> (obese), or</li> <li>• <math>\geq 27 \text{ kg/m}^2</math> to <math>&lt; 30 \text{ kg/m}^2</math> (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.</li> </ul> <p>In a phase III study, liraglutide, as an adjunct to diet and exercise, was associated with significantly reduced body weight compared with placebo in patients with BMI <math>\geq 30 \text{ kg/m}^2</math> or <math>\geq 27 \text{ kg/m}^2</math> if they had dyslipidaemia or hypertension.</p> <p>The submitting company's justification of the treatment's cost in</p>		<a href="#">187</a>	Dec 2021

	relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.			
Liraglutide, 6mg/mL solution for injection in pre-filled pen (Saxenda®)  SMC No: (1247/17)	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of • $\geq 30\text{kg/m}^2$ (obese), or • $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.	Not available as not recommended for use in NHS Scotland	<a href="#">162</a>	Aug 2017
Liraglutide 6mg/ml solution for injection in pre-filled pen (Victoza®)  SMC 1192/16	As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contra-indications.	Not available as not recommended for use in NHS Scotland.	<a href="#">157</a>	Nov 2016
Liraglutide (Victoza®) (1044/15)	Type 2 diabetes mellitus to achieve glycaemic control in combination with: oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.	Formulary - GPs under direction of the Diabetes Clinic  (Endocrine Specialist List)	<a href="#">148</a>	May 2015
Liraglutide (Victoza®)	Type 2 diabetes mellitus	Formulary - GPs under direction of the Diabetes Clinic	<a href="#">98</a> <a href="#">Protocol with insulin (off-label)</a> <a href="#">94</a>	Dec 10/Jan 2011 Aug/Sept 2010 Dec 09/Jan 10
lisdexamfetamine dimesylate	Part of a comprehensive treatment programme for attention	Non Formulary - absence of	<a href="#">151</a>	Sep/Oct 2015

(Elvanse Adult®) (1079/15)	deficit/hyperactivity disorder (ADHD) in adults.	clinician demand		
Lisdexamfetamine dimesylate (Elvanse®) (863/13)	ADHD	GPs under the direction of child psychiatry	<a href="#">127</a>	May 2013
Lixisenatide (Lyxumia®) (903/13)	Type 2 diabetes mellitus	Formulary - GPs under direction of diabetes clinic	<a href="#">130</a>	Sept/Oct 2013
Lomitapide (Lojuxta®) (956/14)	Adults with homozygous familial hypercholesterolaemia (HoFH)	Not recommended	<a href="#">135</a>	Feb/Mar 2014
Loncastuximab tesirine solution for infusion (Zynlonta®) SMC2609	As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.		197 – Awaiting publication	Apr 2024
lopinavir 80mg, ritonavir 20mg oral solution (Kaletra®) SMC No 1302/18	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.	Available in line with national guidance	<a href="#">167</a>	April 2018
Lopinavir 200mg/ritonavir 50mg tablet (Kaletra®)	HIV-1	HOSPITAL ONLY (HIV Clinic)	<a href="#">63</a>	2006
lorlatinib 25mg and 100mg film-coated tablets (Lorviqua®) SMC2415	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">188</a>	April 2022
Lorlatinib 25mg and 100mg film-coated tablets (Lorviqua®) SMC 2239	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: <ul style="list-style-type: none"> <li>• alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or</li> <li>• crizotinib and at least one other ALK TKI</li> </ul> <p>In the relevant subgroup of a non-comparative phase I/II study</p>	Available in line with national guidance	<a href="#">180</a>	Sept 2020

	of previously-treated patients with ALK-positive advanced NSCLC, lorlatinib was associated with an objective response rate of approximately 40%			
Losartan 100mg/hydrochlorothiazide 12.5mg (Cozaar-Comp 100/12.5®)	Hypertension	Non-formulary	<a href="#">77</a>	Mar 2008
Losartan 100mg/hydrochlorothiazide 25mg (Cozaar-Comp ®)	Hypertension	Non-formulary	<a href="#">60</a>	2006
Losartan (Cozaar®)	Diabetic nephropathy	Non-formulary	<a href="#">47</a> <a href="#">46</a>	2004
Losartan (Cozaar®)	Hypertension with LVH		<a href="#">44</a> <a href="#">43</a>	2004
Loteprednol etabonate 0.5% 5mg/ml (Lotemax® 0.5% eye drops) (484/08)	Post operative inflammation following ocular surgery	Not recommended	<a href="#">80</a>	Jun 2008
Lubiprostone (Amitiza®) (977/14)	Chronic idiopathic constipation and associated symptoms in adults.	Not recommended	<a href="#">140</a>	Jul/Aug 2014
Lumacaftor and ivacaftor 200mg/125mg, 100mg/125mg film-coated tablets and 100mg/125mg,150mg/188mg granules in sachets (Orkambi®) SMC2182	The treatment of cystic fibrosis in patients aged 6 years and older (tablets) and aged 2 to 5 years (granules) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Not available as not recommended for use in NHS Scotland	<a href="#">176</a>	Oct 2019
Lumacaftor 200mg, ivacaftor 125mg film coated tablets (Orkambi®) SMC 1136/16	Treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene	Not available as not recommended for use in NHS Scotland	<a href="#">155</a>	June 2016
lumasiran (Oxlumo) SMC2639	Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.	Not available as not recommended for use in NHS	196	Feb 2024

		Scotland		
Lumiracoxib (Prexige®) - Withdrawn November 2007	Osteoarthritis	Withdrawn	<a href="#">56</a>	2006
Lurasidone (Latuda®) (994/14)	Schizophrenia in adults aged 18 years and over	Formulary - GPs may prescribe under the direction of Mental Health	<a href="#">142</a>	Oct/Nov 2014
Lusutrombopag 3mg film-coated tablets (Mulpleo®) SMC 2227	For the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">178</a>	Feb 2020
lutetium (177Lu) vipivotide tetraxetan solution for injection or infusion (Pluvicto®) SMC2517	Treatment of adult patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.	Not available as not recommended for use in NHS Scotland	<a href="#">195</a>	December 2023
Lutetium (177Lu) oxodotreotide 370MBq/mL solution for infusion (Lutathera®) SMC No 1337/18	For the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. In an open-label, phase III study, lutetium (177Lu) oxodotreotide significantly improved progression-free survival compared with a high dose somatostatin analogue in patients with progressive midgut neuroendocrine tumours.	Available in line with National Guidance	<a href="#">170</a>	Sep 2018

Updated: 15<sup>th</sup> March 2024

[Back to top](#)

[Back to homepage](#)